The landscape of modern neuropsychiatry is undergoing a profound structural transformation, driven by the exploration of rapid-acting psychoactive agents. Investigators, clinical researchers, and public health authorities across the United States, Canada, Brazil, Mexico, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, and Switzerland are re-evaluating compounds that deviate from traditional pharmaceutical models. Among these, […]